|Bid||7,900.00 x 0|
|Ask||8,720.00 x 0|
|Day's range||8,440.00 - 8,525.00|
|52-week range||6,499.80 - 8,923.00|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||39.02|
|Forward dividend & yield||2.07 (2.38%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||N/A|
WILMINGTON, Del., July 23, 2021--AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise.
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, which occurred on July 12, 2021. This follows less than three weeks after the June 22, 2021 approval of ORPATHYS® in China for the treatment of patients with locally
WILMINGTON, Del., July 08, 2021--AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.